Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? - Wikidata - wikimedia - TriplyDB

Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?

Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?

http://www.wikidata.org/entity/Q36468050

about

Chemotherapy-related cognitive impairment in older patients with cancer Psychoneuroimmunology and cancer: a decade of discovery, paradigm shifts, and methodological innovations Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study Default mode network as a potential biomarker of chemotherapy-related brain injury Cognitive problems among breast cancer survivors: loneliness enhances risk Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?Prevalence, mechanisms, and management of cancer-related cognitive impairment.Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors.Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine.Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation.Self-reported cognitive concerns and abilities: two sides of one coin?Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study.Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors.Cognitive function and fatigue after diagnosis of colorectal cancer Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer.Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial.Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study Human amniotic epithelial cells inhibit granulosa cell apoptosis induced by chemotherapy and restore the fertility.Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients.Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer A feasibility study exploring the role of pre-operative assessment when examining the mechanism of 'chemo-brain' in breast cancer patients Cytokine genetic variations and fatigue among patients with breast cancer.Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance.Positive Affect and Inflammatory Activity in Breast Cancer Survivors: Examining the Role of Affective Arousal.Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy.Neuroimaging, cancer, and cognition: state of the knowledge.Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research.Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907.Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster.Biomarkers Associated with Cognitive Impairment in Treated Cancer Patients: Potential Predisposition and Risk Factors.Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review.Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.

P2860

Q26747612-95F84318-BFAB-48FE-92C7-39C116E7D07C Q27007708-AAD64F2E-6BA4-494C-9636-FE4F81155D96 Q28075692-42D96710-08A1-4D2C-956F-31307343251B Q30758966-6C81EC80-50D7-481B-A008-E8C2B3B9B4CF Q30830124-7F425A3D-538E-48B7-87B5-77F0C1372CC8 Q33358246-6D9D80C9-97A9-42D0-A742-271C5F13BF02 Q33729085-24796789-9F23-4FCB-93BF-5C03DB1E9BD3 Q33854977-6C19B090-5B9E-413A-B6DC-402488D0A01A Q34031141-F3B0F480-12B1-4982-BD1F-532E266586BD Q34036124-CE290909-DFB9-41C7-8122-991D015385D9 Q34194470-A0BD82FC-252E-42E7-8B4F-CA676DA7550C Q34288191-77A57A7D-FCB1-4B30-9569-A50B9B77299C Q34402534-BC2A33E4-BA9F-48C0-9858-477EC43ABAFF Q34503992-B9B453BA-700A-4784-936F-C8A013B1C0B4 Q34553654-30287FDE-3CD1-41BB-8D70-4963ABCBED81 Q35067446-D30A0351-7F59-48E0-ABB5-F4C6FBEC38B1 Q35164117-FF53B091-6512-43CB-A4F4-D7710F71BC39 Q35446931-673783C4-0C01-4BB8-9836-891176A53A73 Q35513395-A7DDC809-D634-417F-9AB5-BB42A9836E07 Q35536611-279D462F-A855-484E-A774-7FE7F4C9A79E Q35775258-37BE0807-7DC7-4725-A38F-CA8D86384CAE Q35995038-EB6DD199-CF54-40AA-9135-DFCFEADFBA92 Q36152838-F1372DA7-62EB-460B-91CD-7133FE84B3DB Q36173493-F90B58D1-1B79-4DE2-B170-41A8DD7023CB Q36754399-702CE4A1-EE80-4E26-8794-BA66D4050BA0 Q36793285-71AC6A64-E7F8-42D1-AAC5-D384ADBC1B39 Q36813475-A40D5D26-A137-42F9-8A2D-2A7AFC0DA1D8 Q36901307-9035526D-E25C-4F45-AB3C-334A31F55E15 Q37036767-45B587A6-C75D-49B3-8ABF-1C74368E6232 Q37064264-40552E9F-0139-4F44-8B73-66131316156D Q37292321-167CA25C-9864-4FA6-BFA8-ECA473FAED26 Q37431101-DB9231B7-5130-47D1-991F-7E8CF5608D64 Q37540122-F6401579-38EB-4CCB-AAC7-0EC1008EBA74 Q37576583-8D065D8B-959C-4FAA-A1CB-95053EDA39FC Q37633785-3164BF31-4C8B-43FA-9CF9-21988668CE1A Q37712562-251D62E0-58AC-461B-8D69-159B58C18E16 Q38150812-B533C80A-0AE0-4673-AAE5-24A6C4AEEEDB Q38594867-F0F272E3-4F75-4B55-BBD7-F37C911C62B7 Q38786134-E066547C-E90B-410B-8396-F5245AEBF638 Q38848380-2C564975-2445-4FD8-9C66-9B4AB3AF33B5

P2860

Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?

http://www.wikidata.org/entity/Q36468050

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Does tumor necrosis factor-alp ...... otherapy cerebral dysfunction?

@ast

Does tumor necrosis factor-alp ...... otherapy cerebral dysfunction?

@en

type

label

Does tumor necrosis factor-alp ...... otherapy cerebral dysfunction?

@ast

Does tumor necrosis factor-alp ...... otherapy cerebral dysfunction?

@en

prefLabel

Does tumor necrosis factor-alp ...... otherapy cerebral dysfunction?

@ast

Does tumor necrosis factor-alp ...... otherapy cerebral dysfunction?

@en

P1433

Q36468050-8D22CD92-013C-496E-8BCE-025F3BECF93E

P1476

Q36468050-87ED743B-4398-43D3-BE13-578A82135D26

P2093

Q36468050-01203138-57CA-4375-9BC7-24E2954D0A17

Q36468050-0DF2D44C-EC03-459E-A000-0E3588D42CF2

Q36468050-817C067E-5F62-4EF4-83F1-A2772F797F85

Q36468050-8DC13C46-00CC-44F5-BCCA-71AA52750659

Q36468050-9E68BF3D-F0B6-448B-BA6A-955E59EBF4EB

Q36468050-DCC1F815-C8A4-414E-8EBE-1A6A2B88C896

Q36468050-E5AAE2BE-E3D5-4A31-8FF3-18F5E423ADBE

Q36468050-FE7EB8FE-E920-4E3A-A8A9-8F1E876FC0BB

P2860

Q36468050-03BD6E5E-F0F7-4E77-9D64-8E1C064F2228

Q36468050-03CBEAA4-BA01-4B1B-858C-C0BC8767BA15

Q36468050-05499F3E-ACF2-4A25-8354-703D0359AD0D

Q36468050-0BBF0820-7755-43D9-A9BA-A4B3B9D2AE02

Q36468050-0F151414-DD2D-4B4D-A783-D83C2E782A73

Q36468050-0F39F66B-CB27-49DF-97C1-6D51AF53D410

Q36468050-1191A18B-CE5F-419F-9395-9A350647265E

Q36468050-12AD62B9-7892-49D8-AB22-ABE2FDE55F41

Q36468050-1875A7C8-B3FE-4564-BF8A-CE1C26185B58

Q36468050-1E0FBEE3-AFB2-45B0-A7CF-E5D49D9008D4

P304

Q36468050-7A3CDB49-59D0-422D-A1BC-05CD4F8F3536

P31

Q36468050-4927F9BF-318B-47BD-899B-9DD4E79866F8

P356

Q36468050-FEC20F1B-7B4E-449B-A72D-D0CD3B79706D

P478

Q36468050-3C633A3C-6DF5-409D-A7DB-323C272D7483

P50

Q36468050-53D1C062-E1F0-4587-B990-A8CB2FBED001

P577

Q36468050-D3E1F3B6-5285-4133-9A62-E784B3FEFEB1

P5875

Q36468050-0ECFC9FF-C73C-4481-A7CA-10A541509599

P698

Q36468050-21A5B01F-01C6-4BF9-AC3F-289BA59B344A

P921

Q36468050-1F0D9CC5-C5B6-49E1-BEEC-105DADADE98C

Q36468050-C3C41110-D5B8-45D4-B1AF-DD30B4237446

P932

Q36468050-F2C3FFCC-5BC5-4581-AABB-06E6832D9007

P356

J.BBI.2012.07.015

P1433

Brain, Behavior, and Immunity

P1476

Does tumor necrosis factor-alp ...... otherapy cerebral dysfunction?

@en

P2093

C Geist

http://www.w3.org/2001/XMLSchema#string

D H S Silverman

http://www.w3.org/2001/XMLSchema#string

E C Breen

http://www.w3.org/2001/XMLSchema#string

J E Bower

http://www.w3.org/2001/XMLSchema#string

L Kwan

http://www.w3.org/2001/XMLSchema#string

Patricia A Ganz

http://www.w3.org/2001/XMLSchema#string

S A Castellon

http://www.w3.org/2001/XMLSchema#string

S W Cole

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.

Neural sensitivity to social rejection is associated with inflammatory responses to social stress

Cognitive impairment associated with chemotherapy for cancer: report of a workshop

Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy

Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer

Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy.

Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy

Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.

Estrogen use and brain metabolic change in postmenopausal women.

Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain.

P304

S99-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBI.2012.07.015

http://www.w3.org/2001/XMLSchema#string

P478

30 Suppl

http://www.w3.org/2001/XMLSchema#string

P50

Michael R. Irwin

P577

2012-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230653095

http://www.w3.org/2001/XMLSchema#string

P698

22884417

http://www.w3.org/2001/XMLSchema#string

P921

P932

3522786

http://www.w3.org/2001/XMLSchema#string